SPI Pharma Launches Pharmaburst® 500 Microsite

New site to feature proprietary orally disintegrating tablet (ODT) platform, Pharmaburst 500

Jan 14, 2014, 11:00 ET from SPI Pharma

WILMINGTON, Del., Jan. 14, 2014 /PRNewswire/ -- SPI Pharma is proud to announce the launch of the new Pharmaburst 500 website (www.pharmaburst.com).  The new website was designed to assist both R&D formulators and Business Development Managers interested in the development and commercialization of orally disintegrating tablets.  The site offers technical resources including starting formulations as well as information on SPI Pharma's ODT technology platform, taste-masking, and drug development services. 

(Logo: http://photos.prnewswire.com/prnh/20140114/NE43872LOGO)

Pharmaburst was the first fully formulated off-the-shelf orally disintegrating technology designed for direct compression tablet manufacturing on the market.  It is now used in more than 60 commercialized products around the world. Pharmaburst 500, the latest addition to the technology platform, was granted a US patent in December 2013.  This product represents years of ODT experience resulting in an optimized formulation that provides robust tablets with rapid disintegration and superior organoleptic properties. 

"Orally disintegrating tablets are becoming increasingly popular due to their convenience and compliance advantages. They are becoming mainstream in a variety of prescription and OTC medications for treating pain, cough/cold, sleep disorders, GERD, and ED" stated Diane Reitter, Business Manager for SPI Pharma.  "SPI Pharma is uniquely positioned to support our customer's ODT development projects by offering taste-masking and drug development services along with our market leading Pharmaburst technology." 

About SPI Pharma

SPI Pharma (http://www.spipharma.com) is a global leader serving over 55 countries in the manufacture and marketing of antacid actives, excipients, drug delivery systems for tablets, fast-dissolve technologies, chewables, lozenges, and a variety of other patient-friendly dosage formats.  SPI also specializes in drug development services, delivering in-vitro data packages in CTD Module 3.2 format.